Integra LifeSciences IART Proceeds from secured term loan
Proceeds from secured term loan at other companies
Other financials
Where this comes from
Reported directly by Integra LifeSciences in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSecuredDebt.
The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Integra LifeSciences's proceeds from secured term loan.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Integra LifeSciences's proceeds from secured term loan?
- Integra LifeSciences (IART) reported proceeds from secured term loan of $44.5M in Q1 2026.
- How has Integra LifeSciences's proceeds from secured term loan changed year-over-year?
- Integra LifeSciences's proceeds from secured term loan decreased by 18.2% year-over-year, from $54.4M to $44.5M.
- What is the long-term trend for Integra LifeSciences's proceeds from secured term loan?
- Over 4 years (2021 to 2025), Integra LifeSciences's proceeds from secured term loan has grown at a 130.6% compound annual growth rate (CAGR), from $25.5M to $720.7M.
- What does proceeds from secured term loan mean?
- This represents the cash proceeds received from the issuance of debt instruments that are backed by specific company assets as collateral. It indicates the company's ability to access secured financing markets to fund operations, acquisitions, or debt refinancing. Monitoring this helps investors assess the company's leverage profile and its reliance on secured versus unsecured funding.